Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age

AIDS

Volumn 26, Issue 12, 2012, Pages 1483-1490

  Persaud, Deborah ^a   Palumbo, Paul E ^b   Ziemniak, Carrie ^a   Hughes, Michael D ^c   Alvero, Carmelita G ^c   Luzuriaga, Katherine ^d   Yogev, Ram ^e   Capparelli, Edmund V ^f   Chadwick, Ellen G ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

early HAART; infants; latent reservoir dynamics

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE CARRIER; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LOPINAVIR; MALE; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84864290338     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283553638     Document Type: Article

References (30)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS): UNAIDS Report in the Global AIDS Epidemic.December. 2010. http://www.unaids.org,in/Publications- ReportonThe GlobalAIDSEpidemic2010.pdf Accessed 23 November 2010.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf Accessed 27 March 2012.
3. Guidelines for the use of antiretroviral agents in pediatric HIVinfection.http://aidsinfo.nih.gov/Contentfiles/lvguidelines/ recommendations-only-Ped-2011.pdf. Accessed 11 August 2011
4. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973-980.
5. + T cells. Nature 2002; 417:95-98.
6. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-593.
7. (+) T lymphocytes in infected children. J Clin Invest 2000; 105:995-1003.
8. Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002; 76:9481-9492.
9. (+) T cells. Nat Med 2003; 9:727-728.
10. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
11. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000; 6:82-85.
12. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22:249-255.
13. Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J 2009; 28:215-219.
14. + T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
15. Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195:1402-1410.
16. Persaud D, Ray SC, Kajdas J, Ahonkhai A, Siberry GK, Ferguson K, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:381-390.
17. + T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
18. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
19. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
20. + infection but does not accelerate the decay in latent infection abstract 152. In: 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 2012.
21. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship Between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
22. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
23. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 1999; 73:362-367.
24. Melvin AJ, Rodrigo AG, Mohan KM, Lewis PA, Manns-Arcuino L, Coombs RW, et al. HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:468-473.
25. Palumbo P, Wu H, Chadwick E, Ruan P, Luzuriaga K, Rodman J, et al. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J Infect Dis 2007; 196:23-29.
26. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
27. Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97:10966-10971.
28. Moyle G, Demasi R, Hill A. Does earlier HIV RNA suppression provide long-term benefits? AIDS 2010; 24:1591-1593.
29. + memory cells and residual viremia in patients on ART: results from ACTG A5173 abstract. In: 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle.
30. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321.